FGFR2 and non-small cell lung carcinoma: The majority of SNVs in FGFR have been reported to occur in FGFR2 and are found at high frequencies in endometrial cancer (12%), non-small cell lung cancer (4%) and gastric cancer (4%).1,19,20 Interestingly, these somatic-activating FGFR2 mutations predominantly occur in the transmembrane (Y375C, C382Y/R) and extracellular domains (S252W, W290C, P253R) rather than the kinase domain (N549H/K, K659E).3 Extensive in vitro and in vivo analyses of these mutations have revealed that their oncogenic potential is due to increased receptor–ligand binding affinity and receptor dimerisation.